6 O
. O

ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
labeling O
: O
* O
Cardiovascular B-OSE_Labeled_AE
Thrombotic I-OSE_Labeled_AE
Events I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
GI B-OSE_Labeled_AE
Bleeding I-OSE_Labeled_AE
, O
Ulceration O
and O
Perforation O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Hepatotoxicity B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Hypertension B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Heart B-OSE_Labeled_AE
Failure I-OSE_Labeled_AE
and O
Edema B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Renal B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
and O
Hyperkalemia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Anaphylactic B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Serious B-OSE_Labeled_AE
Skin I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Hematologic B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
in O
arthritis O
trials O
( O
> O
2 O
% O
and O
> O
placebo O
) O
are O
: O
abdominal O
pain O
, O
diarrhea O
, O
dyspepsia O
, O
flatulence O
, O
peripheral O
edema O
, O
accidental O
injury O
, O
dizziness O
, O
pharyngitis O
, O
rhinitis O
, O
sinusitis O
, O
upper O
respiratory O
tract O
infection O
, O
rash O
( O
6.1 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Pfizer O
at O
1-800-438-1985 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
adverse O
reaction O
information O
from O
clinical O
trials O
does O
, O
however O
, O
provide O
a O
basis O
for O
identifying O
the O
adverse O
events O
that O
appear O
to O
be O
related O
to O
drug O
use O
and O
for O
approximating O
rates O
. O

Of O
the O
CELEBREX-treated O
patients O
in O
the O
pre-marketing O
controlled O
clinical O
trials O
, O
approximately O
4,250 O
were O
patients O
with O
OA B-Not_AE_Candidate
, O
approximately O
2,100 O
were O
patients O
with O
RA B-Not_AE_Candidate
, O
and O
approximately O
1,050 O
were O
patients O
with O
post B-Not_AE_Candidate
- I-Not_AE_Candidate
surgical I-Not_AE_Candidate
pain I-Not_AE_Candidate
. O

More O
than O
8,500 O
patients O
received O
a O
total O
daily O
dose O
of O
CELEBREX O
of O
200 O
mg O
( O
100 O
mg O
twice O
daily O
or O
200 O
mg O
once O
daily O
) O
or O
more O
, O
including O
more O
than O
400 O
treated O
at O
800 O
mg O
( O
400 O
mg O
twice O
daily O
) O
. O

Approximately O
3,900 O
patients O
received O
CELEBREX O
at O
these O
doses O
for O
6 O
months O
or O
more O
; O
approximately O
2,300 O
of O
these O
have O
received O
it O
for O
1 O
year O
or O
more O
and O
124 O
of O
these O
have O
received O
it O
for O
2 O
years O
or O
more O
. O

Pre-marketing O
Controlled O
Arthritis O
Trials O
Table O
1 O
lists O
all O
adverse O
events O
, O
regardless O
of O
causality O
, O
occurring O
in O
> O
=2 O
% O
of O
patients O
receiving O
CELEBREX O
from O
12 O
controlled O
studies O
conducted O
in O
patients O
with O
OA B-Not_AE_Candidate
or O
RA B-Not_AE_Candidate
that O
included O
a O
placebo O
and/or O
a O
positive O
control O
group O
. O

Since O
these O
12 O
trials O
were O
of O
different O
durations O
, O
and O
patients O
in O
the O
trials O
may O
not O
have O
been O
exposed O
for O
the O
same O
duration O
of O
time O
, O
these O
percentages O
do O
not O
capture O
cumulative O
rates O
of O
occurrence O
. O

Table O
1 O
: O
Adverse O
Events O
Occurring O
in O
> O
=2 O
% O
of O
CELEBREX O
Patients O
from O
Pre-marketing O
Controlled O
Arthritis O
Trials O
CBXN=4146 O
PlaceboN=1864 O
NAPN=1366 O
DCFN=387 O
IBUN=345 O
CBX O
= O
CELEBREX O
100 O
- O
200 O
mg O
twice O
daily O
or O
200 O
mg O
once O
daily O
; O
NAP O
= O
Naproxen O
500 O
mg O
twice O
daily O
; O
DCF O
= O
Diclofenac O
75 O
mg O
twice O
daily O
; O
IBU O
= O
Ibuprofen O
800 O
mg O
three O
times O
daily O
. O

Gastrointestinal B-NonOSE_AE
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
4.1 O
% O
2.8 O
% O
7.7 O
% O
9.0 O
% O
9.0 O
% O
Diarrhea B-OSE_Labeled_AE
5.6 O
% O
3.8 O
% O
5.3 O
% O
9.3 O
% O
5.8 O
% O
Dyspepsia B-OSE_Labeled_AE
8.8 O
% O
6.2 O
% O
12.2 O
% O
10.9 O
% O
12.8 O
% O
Flatulence B-OSE_Labeled_AE
2.2 O
% O
1.0 O
% O
3.6 O
% O
4.1 O
% O
3.5 O
% O
Nausea B-OSE_Labeled_AE
3.5 O
% O
4.2 O
% O
6.0 O
% O
3.4 O
% O
6.7 O
% O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
whole I-NonOSE_AE
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
2.8 O
% O
3.6 O
% O
2.2 O
% O
2.6 O
% O
0.9 O
% O
Peripheral B-OSE_Labeled_AE
Edema I-OSE_Labeled_AE
2.1 O
% O
1.1 O
% O
2.1 O
% O
1.0 O
% O
3.5 O
% O
Injury B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Accidental I-OSE_Labeled_AE
2.9 O
% O
2.3 O
% O
3.0 O
% O
2.6 O
% O
3.2 O
% O
Central B-NonOSE_AE
, I-NonOSE_AE
Peripheral I-NonOSE_AE
Nervous I-NonOSE_AE
system I-NonOSE_AE
Dizziness B-OSE_Labeled_AE
2.0 O
% O
1.7 O
% O
2.6 O
% O
1.3 O
% O
2.3 O
% O
Headache B-OSE_Labeled_AE
15.8 O
% O
20.2 O
% O
14.5 O
% O
15.5 O
% O
15.4 O
% O
Psychiatric B-NonOSE_AE
Insomnia B-OSE_Labeled_AE
2.3 O
% O
2.3 O
% O
2.9 O
% O
1.3 O
% O
1.4 O
% O
Respiratory B-NonOSE_AE
Pharyngitis B-OSE_Labeled_AE
2.3 O
% O
1.1 O
% O
1.7 O
% O
1.6 O
% O
2.6 O
% O
Rhinitis B-OSE_Labeled_AE
2.0 O
% O
1.3 O
% O
2.4 O
% O
2.3 O
% O
0.6 O
% O
Sinusitis B-OSE_Labeled_AE
5.0 O
% O
4.3 O
% O
4.0 O
% O
5.4 O
% O
5.8 O
% O
Upper B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
8.1 O
% O
6.7 O
% O
9.9 O
% O
9.8 O
% O
9.9 O
% O
Skin B-NonOSE_AE
Rash B-OSE_Labeled_AE
2.2 O
% O
2.1 O
% O
2.1 O
% O
1.3 O
% O
1.2 O
% O
In O
placebo- O
or O
active-controlled O
clinical O
trials O
, O
the O
discontinuation O
rate O
due O
to O
adverse O
events O
was O
7.1 O
% O
for O
patients O
receiving O
CELEBREX O
and O
6.1 O
% O
for O
patients O
receiving O
placebo O
. O

Among O
the O
most O
common O
reasons O
for O
discontinuation O
due O
to O
adverse O
events O
in O
the O
CELEBREX O
treatment O
groups O
were O
dyspepsia B-OSE_Labeled_AE
and O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
cited O
as O
reasons O
for O
discontinuation O
in O
0.8 O
% O
and O
0.7 O
% O
of O
CELEBREX O
patients O
, O
respectively O
) O
. O

Among O
patients O
receiving O
placebo O
, O
0.6 O
% O
discontinued O
due O
to O
dyspepsia B-NonOSE_AE
and O
0.6 O
% O
withdrew O
due O
to O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
. O

The O
following O
adverse O
reactions O
occurred O
in O
0.1 O
- O
1.9 O
% O
of O
patients O
treated O
with O
CELEBREX O
( O
100 O
- O
200 O
mg O
twice O
daily O
or O
200 O
mg O
once O
daily O
) O
: O
Gastrointestinal B-NonOSE_AE
: O
Constipation B-OSE_Labeled_AE
, O
diverticulitis B-OSE_Labeled_AE
, O
dysphagia B-OSE_Labeled_AE
, O
eructation B-OSE_Labeled_AE
, O
esophagitis B-OSE_Labeled_AE
, O
gastritis B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
, O
gastroesophageal B-OSE_Labeled_AE
reflux I-OSE_Labeled_AE
, O
hemorrhoids B-OSE_Labeled_AE
, O
hiatal B-OSE_Labeled_AE
hernia I-OSE_Labeled_AE
, O
melena B-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
tenesmus B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
Cardiovascular B-NonOSE_AE
: O
Aggravated B-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
, O
angina B-OSE_Labeled_AE
pectoris I-OSE_Labeled_AE
, O
coronary B-OSE_Labeled_AE
artery I-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
General B-NonOSE_AE
: O
Hypersensitivity B-OSE_Labeled_AE
, O
allergic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
cyst B-OSE_Labeled_AE
NOS I-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
generalized I-OSE_Labeled_AE
, O
face B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
, O
hot B-OSE_Labeled_AE
flushes I-OSE_Labeled_AE
, O
influenza B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
Central B-NonOSE_AE
, I-NonOSE_AE
peripheral I-NonOSE_AE
nervous I-NonOSE_AE
system I-NonOSE_AE
: O
Leg B-OSE_Labeled_AE
cramps I-OSE_Labeled_AE
, O
hypertonia B-OSE_Labeled_AE
, O
hypoesthesia B-OSE_Labeled_AE
, O
migraine B-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
, O
vertigo B-OSE_Labeled_AE
Hearing B-NonOSE_AE
and I-NonOSE_AE
vestibular I-NonOSE_AE
: O
Deafness B-OSE_Labeled_AE
, O
tinnitus B-OSE_Labeled_AE
Heart B-NonOSE_AE
rate I-NonOSE_AE
and I-NonOSE_AE
rhythm I-NonOSE_AE
: O
Palpitation B-OSE_Labeled_AE
, O
tachycardia B-OSE_Labeled_AE
Liver B-NonOSE_AE
and I-NonOSE_AE
biliary I-NonOSE_AE
: O
Hepatic B-OSE_Labeled_AE
enzyme I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
including O
SGOT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
SGPT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
) O
Metabolic B-NonOSE_AE
and I-NonOSE_AE
nutritional I-NonOSE_AE
: O
BUN B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
CPK B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
hypercholesterolemia B-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
hypokalemia B-OSE_Labeled_AE
, O
NPN B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
creatinine B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
alkaline B-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
Musculoskeletal B-NonOSE_AE
: O
Arthralgia B-OSE_Labeled_AE
, O
arthrosis B-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
, O
synovitis B-OSE_Labeled_AE
, O
tendinitis B-OSE_Labeled_AE
Platelets B-NonOSE_AE
( I-NonOSE_AE
bleeding I-NonOSE_AE
or I-NonOSE_AE
clotting I-NonOSE_AE
) O
: O
Ecchymosis B-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
thrombocythemia B-OSE_Labeled_AE
, O
Psychiatric B-NonOSE_AE
: O
Anorexia B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
appetite B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
nervousness B-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
Hemic B-NonOSE_AE
: O
Anemia B-OSE_Labeled_AE
Respiratory B-NonOSE_AE
: O
Bronchitis B-OSE_Labeled_AE
, O
bronchospasm B-OSE_Labeled_AE
, O
bronchospasm B-OSE_Labeled_AE
aggravated I-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
laryngitis B-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
appendages I-NonOSE_AE
: O
Alopecia B-OSE_Labeled_AE
, O
dermatitis B-OSE_Labeled_AE
, O
photosensitivity B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
erythematous I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
maculopapular I-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
dry I-OSE_Labeled_AE
, O
sweating B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
Application B-NonOSE_AE
site I-NonOSE_AE
disorders I-NonOSE_AE
: O
Cellulitis B-OSE_Labeled_AE
, O
dermatitis B-OSE_Labeled_AE
contact I-OSE_Labeled_AE
Urinary B-NonOSE_AE
: O
Albuminuria B-OSE_Labeled_AE
, O
cystitis B-OSE_Labeled_AE
, O
dysuria B-OSE_Labeled_AE
, O
hematuria B-OSE_Labeled_AE
, O
micturition B-OSE_Labeled_AE
frequency I-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
calculus I-OSE_Labeled_AE
The O
following O
serious O
adverse O
events O
( O
causality O
not O
evaluated O
) O
occurred O
in O
< O
0.1 O
% O
of O
patients O
: O
Cardiovascular B-NonOSE_AE
: O
Syncope B-OSE_Labeled_AE
, O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
, O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
gangrene I-OSE_Labeled_AE
, O
thrombophlebitis B-OSE_Labeled_AE
Gastrointestinal B-NonOSE_AE
: O
Intestinal B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
, O
intestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
, O
colitis B-OSE_Labeled_AE
with I-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
, O
esophageal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
, O
pancreatitis B-OSE_Labeled_AE
, O
ileus B-OSE_Labeled_AE
General B-NonOSE_AE
: O
Sepsis B-OSE_Labeled_AE
, O
sudden B-OSE_Labeled_AE
death I-OSE_Labeled_AE
Liver B-NonOSE_AE
and I-NonOSE_AE
biliary I-NonOSE_AE
: O
Cholelithiasis B-OSE_Labeled_AE
Hemic B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
: O
Thrombocytopenia B-OSE_Labeled_AE
Nervous B-NonOSE_AE
: O
Ataxia B-OSE_Labeled_AE
, O
suicide B-OSE_Labeled_AE
[ O
see O
Drug O
Interactions O
( O
7.1 O
) O
] O
Renal B-NonOSE_AE
: O
Acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
The O
Celecoxib O
Long-Term O
Arthritis B-Not_AE_Candidate
Safety O
Study O
[ O
see O
Special O
Studies O
( O
14.6 O
) O
] O
Hematological B-NonOSE_AE
Events I-NonOSE_AE
: O
The O
incidence O
of O
clinically O
significant O
decreases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
( O
> O
2 O
g/dL O
) O
was O
lower O
in O
patients O
on O
CELEBREX O
400 O
mg O
twice O
daily O
( O
0.5 O
% O
) O
compared O
to O
patients O
on O
either O
diclofenac O
75 O
mg O
twice O
daily O
( O
1.3 O
% O
) O
or O
ibuprofen O
800 O
mg O
three O
times O
daily O
1.9 O
% O
. O

The O
lower O
incidence O
of O
events O
with O
CELEBREX O
was O
maintained O
with O
or O
without O
aspirin O
use O
[ O
see O
Clinical O
Pharmacology O
( O
12.2 O
) O
] O
. O

Withdrawals B-NonOSE_AE
/ O
Serious B-NonOSE_AE
Adverse I-NonOSE_AE
Events I-NonOSE_AE
: O
Kaplan-Meier O
cumulative O
rates O
at O
9 O
months O
for O
withdrawals O
due O
to O
adverse O
events O
for O
CELEBREX O
, O
diclofenac O
and O
ibuprofen O
were O
24 O
% O
, O
29 O
% O
, O
and O
26 O
% O
, O
respectively O
. O

Rates O
for O
serious O
adverse O
events O
( O
i.e. O
, O
causing O
hospitalization O
or O
felt O
to O
be O
life-threatening O
or O
otherwise O
medically O
significant O
) O
, O
regardless O
of O
causality O
, O
were O
not O
different O
across O
treatment O
groups O
( O
8 O
% O
, O
7 O
% O
, O
and O
8 O
% O
, O
respectively O
) O
. O

Juvenile O
Rheumatoid O
Arthritis O
Study O
In O
a O
12-week O
, O
double-blind O
, O
active-controlled O
study O
, O
242 O
JRA B-Not_AE_Candidate
patients O
2 O
years O
to O
17 O
years O
of O
age O
were O
treated O
with O
celecoxib O
or O
naproxen O
; O
77 O
JRA B-Not_AE_Candidate
patients O
were O
treated O
with O
celecoxib O
3 O
mg/kg O
twice O
daily O
, O
82 O
patients O
were O
treated O
with O
celecoxib O
6 O
mg/kg O
twice O
daily O
, O
and O
83 O
patients O
were O
treated O
with O
naproxen O
7.5 O
mg/kg O
twice O
daily O
. O

The O
most O
commonly O
occurring O
( O
> O
=5 O
% O
) O
adverse O
events O
in O
celecoxib O
treated O
patients O
were O
headache B-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
( O
pyrexia B-OSE_Labeled_AE
) O
, O
upper B-OSE_Labeled_AE
abdominal I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
, O
nasopharyngitis B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
arthralgia B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
and O
vomiting B-OSE_Labeled_AE
. O

The O
most O
commonly O
occurring O
( O
> O
=5 O
% O
) O
adverse O
experiences O
for O
naproxen-treated O
patients O
were O
headache B-NonOSE_AE
, O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
fever B-NonOSE_AE
, O
upper B-NonOSE_AE
abdominal I-NonOSE_AE
pain I-NonOSE_AE
, O
diarrhea B-NonOSE_AE
, O
cough B-NonOSE_AE
, O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
, O
and O
dizziness B-NonOSE_AE
( O
Table O
2 O
) O
. O

Compared O
with O
naproxen O
, O
celecoxib O
at O
doses O
of O
3 O
and O
6 O
mg/kg O
twice O
daily O
had O
no O
observable O
deleterious B-NonOSE_AE
effect I-NonOSE_AE
on I-NonOSE_AE
growth O
and O
development I-NonOSE_AE
during O
the O
course O
of O
the O
12-week O
double-blind O
study O
. O

There O
was O
no O
substantial O
difference O
in O
the O
number O
of O
clinical O
exacerbations B-NonOSE_AE
of I-NonOSE_AE
uveitis I-NonOSE_AE
or O
systemic O
features O
of O
JRA B-Not_AE_Candidate
among O
treatment O
groups O
. O

In O
a O
12-week O
, O
open-label O
extension O
of O
the O
double-blind O
study O
described O
above O
, O
202 O
JRA B-Not_AE_Candidate
patients O
were O
treated O
with O
celecoxib O
6 O
mg/kg O
twice O
daily O
. O

The O
incidence O
of O
adverse O
events O
was O
similar O
to O
that O
observed O
during O
the O
double-blind O
study O
; O
no O
unexpected O
adverse O
events O
of O
clinical O
importance O
emerged O
. O

Table O
2 O
: O
Adverse O
Events O
Occurring O
in O
> O
=5 O
% O
of O
JRA O
Patients O
in O
Any O
Treatment O
Group O
, O
by O
System O
Organ O
Class O
( O
% O
of O
patients O
with O
events O
) O
All O
Doses O
Twice O
Daily O
System O
Organ O
Class O
Preferred O
Term O
Celecoxib3 O
mg/kgN=77 O
Celecoxib6 O
mg/kgN=82 O
Naproxen7.5 O
mg/kgN=83 O
Any O
Event O
64 O
70 O
72 O
Eye B-OSE_Labeled_AE
Disorders I-OSE_Labeled_AE
5 O
5 O
5 O
Gastrointestinal B-NonOSE_AE
26 O
24 O
36 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
NOS O
4 O
7 O
7 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
8 O
6 O
10 O
Vomiting B-OSE_Labeled_AE
NOS O
3 O
6 O
11 O
Diarrhea B-OSE_Labeled_AE
NOS O
5 O
4 O
8 O
Nausea B-OSE_Labeled_AE
7 O
4 O
11 O
General B-NonOSE_AE
13 O
11 O
18 O
Pyrexia B-OSE_Labeled_AE
8 O
9 O
11 O
Infections B-OSE_Labeled_AE
25 O
20 O
27 O
Nasopharyngitis B-OSE_Labeled_AE
5 O
6 O
5 O
Injury B-NonOSE_AE
and I-NonOSE_AE
Poisoning I-NonOSE_AE
4 O
6 O
5 O
Investigations B-NonOSE_AE
[ O
note O
: O
Abnormal B-NonOSE_AE
laboratory I-NonOSE_AE
tests I-NonOSE_AE
, O
which O
include O
: O
Prolonged B-OSE_Labeled_AE
activated I-OSE_Labeled_AE
partial I-OSE_Labeled_AE
thromboplastin I-OSE_Labeled_AE
time I-OSE_Labeled_AE
, O
Bacteriuria B-OSE_Labeled_AE
NOS O
present O
, O
Blood B-OSE_Labeled_AE
creatine I-OSE_Labeled_AE
phosphokinase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
Blood B-OSE_Labeled_AE
culture I-OSE_Labeled_AE
positive I-OSE_Labeled_AE
, O
Blood B-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
Blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
Blood B-OSE_Labeled_AE
uric I-OSE_Labeled_AE
acid I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
Hematocrit B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
Hematuria B-OSE_Labeled_AE
present I-OSE_Labeled_AE
, O
Hemoglobin B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
Liver B-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
NOS O
abnormal I-OSE_Labeled_AE
, O
Proteinuria B-OSE_Labeled_AE
present O
, O
Transaminase B-OSE_Labeled_AE
NOS O
increased I-OSE_Labeled_AE
, O
Urine B-OSE_Labeled_AE
analysis I-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
NOS O
] O
3 O
11 O
7 O
Musculoskeletal B-NonOSE_AE
8 O
10 O
17 O
Arthralgia B-OSE_Labeled_AE
3 O
7 O
4 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
17 O
11 O
21 O
Headache B-OSE_Labeled_AE
NOS O
13 O
10 O
16 O
Dizziness B-OSE_Labeled_AE
( O
excl O
vertigo B-NonOSE_AE
) O
1 O
1 O
7 O
Respiratory B-NonOSE_AE
8 O
15 O
15 O
Cough B-OSE_Labeled_AE
7 O
7 O
8 O
Skin B-NonOSE_AE
& I-NonOSE_AE
Subcutaneous I-NonOSE_AE
10 O
7 O
18 O
Other O
Pre-Approval O
Studies O
Adverse O
Events O
from O
Ankylosing B-Not_AE_Candidate
Spondylitis I-Not_AE_Candidate
Studies O
: O
A O
total O
of O
378 O
patients O
were O
treated O
with O
CELEBREX O
in O
placebo- O
and O
active-controlled O
AS B-Not_AE_Candidate
studies O
. O

Doses O
up O
to O
400 O
mg O
once O
daily O
were O
studied O
. O

The O
types O
of O
adverse O
events O
reported O
in O
the O
AS B-Not_AE_Candidate
studies O
were O
similar O
to O
those O
reported O
in O
the O
OA B-Not_AE_Candidate
/ O
RA B-Not_AE_Candidate
studies O
. O

Adverse O
Events O
from O
Analgesia B-Not_AE_Candidate
and O
Dysmenorrhea B-Not_AE_Candidate
Studies O
: O
Approximately O
1,700 O
patients O
were O
treated O
with O
CELEBREX O
in O
analgesia B-Not_AE_Candidate
and O
dysmenorrhea B-Not_AE_Candidate
studies O
. O

All O
patients O
in O
post B-Not_AE_Candidate
- I-Not_AE_Candidate
oral I-Not_AE_Candidate
surgery I-Not_AE_Candidate
pain I-Not_AE_Candidate
studies O
received O
a O
single O
dose O
of O
study O
medication O
. O

Doses O
up O
to O
600 O
mg/day O
of O
CELEBREX O
were O
studied O
in O
primary O
dysmenorrhea B-Not_AE_Candidate
and O
post B-Not_AE_Candidate
- I-Not_AE_Candidate
orthopedic I-Not_AE_Candidate
surgery I-Not_AE_Candidate
pain I-Not_AE_Candidate
studies O
. O

The O
types O
of O
adverse O
events O
in O
the O
analgesia B-Not_AE_Candidate
and O
dysmenorrhea B-Not_AE_Candidate
studies O
were O
similar O
to O
those O
reported O
in O
arthritis B-Not_AE_Candidate
studies O
. O

The O
only O
additional O
adverse O
event O
reported O
was O
post B-OSE_Labeled_AE
- I-OSE_Labeled_AE
dental I-OSE_Labeled_AE
extraction I-OSE_Labeled_AE
alveolar I-OSE_Labeled_AE
osteitis I-OSE_Labeled_AE
( O
dry B-OSE_Labeled_AE
socket I-OSE_Labeled_AE
) O
in O
the O
post B-Not_AE_Candidate
- I-Not_AE_Candidate
oral I-Not_AE_Candidate
surgery I-Not_AE_Candidate
pain I-Not_AE_Candidate
studies O
. O

The O
APC O
and O
PreSAP O
Trials O
Adverse O
reactions O
from O
long-term O
, O
placebo-controlled O
polyp B-Not_AE_Candidate
prevention O
studies O
: O
Exposure O
to O
CELEBREX O
in O
the O
APC O
and O
PreSAP O
trials O
was O
400 O
to O
800 O
mg O
daily O
for O
up O
to O
3 O
years O
[ O
see O
Special O
Studies O
Adenomatous B-Not_AE_Candidate
Polyp I-Not_AE_Candidate
Prevention O
Studies O
( O
14.6 O
) O
] O
. O

Some O
adverse O
reactions O
occurred O
in O
higher O
percentages O
of O
patients O
than O
in O
the O
arthritis B-Not_AE_Candidate
pre-marketing O
trials O
( O
treatment O
durations O
up O
to O
12 O
weeks O
; O
see O
Adverse O
events O
from O
CELEBREX O
pre-marketing O
controlled O
arthritis B-Not_AE_Candidate
trials O
, O
above O
) O
. O

The O
adverse O
reactions O
for O
which O
these O
differences O
in O
patients O
treated O
with O
CELEBREX O
were O
greater O
as O
compared O
to O
the O
arthritis B-Not_AE_Candidate
pre-marketing O
trials O
were O
as O
follows O
: O
CELEBREX O
( O
400 O
to O
800 O
mg O
daily O
) O
N O
= O
2285 O
PlaceboN=1303 O
Diarrhea B-OSE_Labeled_AE
10.5 O
% O
7.0 O
% O
Gastroesophageal B-OSE_Labeled_AE
reflux I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
4.7 O
% O
3.1 O
% O
Nausea B-OSE_Labeled_AE
6.8 O
% O
5.3 O
% O
Vomiting B-OSE_Labeled_AE
3.2 O
% O
2.1 O
% O
Dyspnea B-OSE_Labeled_AE
2.8 O
% O
1.6 O
% O
Hypertension B-OSE_Labeled_AE
12.5 O
% O
9.8 O
% O
Nephrolithiasis B-OSE_Labeled_AE
2.1 O
% O
0.8 O
% O
The O
following O
additional O
adverse O
reactions O
occurred O
in O
> O
=0.1 O
% O
and O
< O
1 O
% O
of O
patients O
taking O
CELEBREX O
, O
at O
an O
incidence O
greater O
than O
placebo O
in O
the O
long-term O
polyp B-Not_AE_Candidate
prevention O
studies O
, O
and O
were O
either O
not O
reported O
during O
the O
controlled O
arthritis B-Not_AE_Candidate
pre-marketing O
trials O
or O
occurred O
with O
greater O
frequency O
in O
the O
long-term O
, O
placebo-controlled O
polyp B-Not_AE_Candidate
prevention O
studies O
: O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
Cerebral B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
Eye B-NonOSE_AE
disorders I-NonOSE_AE
: O
Vitreous B-OSE_Labeled_AE
floaters I-OSE_Labeled_AE
, O
conjunctival B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
Ear B-NonOSE_AE
and I-NonOSE_AE
labyrinth I-NonOSE_AE
: O
Labyrinthitis B-OSE_Labeled_AE
Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
: O
Angina B-OSE_Labeled_AE
unstable I-OSE_Labeled_AE
, O
aortic B-OSE_Labeled_AE
valve I-OSE_Labeled_AE
incompetence I-OSE_Labeled_AE
, O
coronary B-OSE_Labeled_AE
artery I-OSE_Labeled_AE
atherosclerosis I-OSE_Labeled_AE
, O
sinus B-OSE_Labeled_AE
bradycardia I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
hypertrophy I-OSE_Labeled_AE
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
: O
Deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
Reproductive B-NonOSE_AE
system I-NonOSE_AE
and I-NonOSE_AE
breast I-NonOSE_AE
disorders I-NonOSE_AE
: O
Ovarian B-OSE_Labeled_AE
cyst I-OSE_Labeled_AE
Investigations B-NonOSE_AE
: O
Blood B-OSE_Labeled_AE
potassium I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
blood B-OSE_Labeled_AE
sodium I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
blood B-OSE_Labeled_AE
testosterone I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
Injury B-NonOSE_AE
, I-NonOSE_AE
poisoning I-NonOSE_AE
and I-NonOSE_AE
procedural I-NonOSE_AE
complications I-NonOSE_AE
: O
Epicondylitis B-OSE_Labeled_AE
, O
tendon B-OSE_Labeled_AE
rupture I-OSE_Labeled_AE
6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post O
approval O
use O
of O
CELEBREX O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
Cardiovascular B-NonOSE_AE
: O
Vasculitis B-OSE_Labeled_AE
, O
deep B-OSE_Labeled_AE
venous I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
General B-NonOSE_AE
: O
Anaphylactoid B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
Liver B-NonOSE_AE
and I-NonOSE_AE
biliary I-NonOSE_AE
: O
Liver B-OSE_Labeled_AE
necrosis I-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
, O
jaundice B-OSE_Labeled_AE
, O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
Hemic B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
: O
Agranulocytosis B-OSE_Labeled_AE
, O
aplastic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
pancytopenia B-OSE_Labeled_AE
, O
leucopenia B-OSE_Labeled_AE
Metabolic B-NonOSE_AE
: O
Hypoglycemia B-OSE_Labeled_AE
, O
hyponatremia B-OSE_Labeled_AE
Nervous B-NonOSE_AE
: O
Aseptic B-OSE_Labeled_AE
meningitis I-OSE_Labeled_AE
, O
ageusia B-OSE_Labeled_AE
, O
anosmia B-OSE_Labeled_AE
, O
fatal B-NonOSE_AE
intracranial B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
Renal B-NonOSE_AE
: O
Interstitial B-OSE_Labeled_AE
nephritis I-OSE_Labeled_AE

